The clinical development of PLK1 inhibitors for NSCLC faces challenges due to their narrow therapeutic window and dose-limiting toxicity, highlighting the need for therapeutic index optimization and a better understanding of the mechanisms of PLK1 inhibition to advance effective combination therapies [29]. Here, PLK1 is linked to non-small cell lung carcinoma.